PEAT Act of 2026
Thyroid Medication: New Rules for Drug Classification
The PEAT Act of 2026 is currently in the early stages of the legislative process. It was recently introduced and sent to the House Committee on Energy and Commerce for review. There are no upcoming votes scheduled at this time.
Legislative Progress
This is a specific technical bill with only two sponsors. It has a long way to go through the committee process before it could become law.
Key Points
- This bill changes the legal definition of a biological product. It states that a medicine cannot be labeled as a biologic just because it contains a protein that is inactive and does not help treat the illness.
- The change specifically targets thyroid medications. By keeping these drugs from being classified as biologics, the bill aims to ensure they remain easier to produce and more accessible for patients.
- This matters because biological products often face stricter and more expensive regulations. If thyroid drugs were forced into that category, it could lead to higher costs or fewer options for people who need them.
Impact Analysis
Govbase has not yet run an impact analysis on this legislation.
Milestones
Referred to the House Committee on Energy and Commerce.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
News
No related news coverage found for this legislation yet.
Source Information
Document Type
Congressional Bill
Official Title
PEAT Act of 2026
Data Sources
Sponsor
Cosponsors
(4)Analysis generated by AI. Always verify with official sources.